G1 Therapeutics Inc (NASDAQ: GTHX) – Analyst View Looks Different Today

In the latest trading session,, 1.57 million G1 Therapeutics Inc (NASDAQ:GTHX) shares changed hands as the company’s beta touched 1.76. With the company’s most recent per share price at $3.54 changed hands at -$0.55 or -13.45% at last look, the market valuation stands at $185.07M. GTHX’s current price is a discount, trading about -73.45% off its 52-week high of $6.14. The share price had its 52-week low at $1.08, which suggests the last value was 69.49% up since then. When we look at G1 Therapeutics Inc’s average trading volume, we note the 3-month average coming to 1.38 million.

G1 Therapeutics Inc (NASDAQ:GTHX) trade information

Instantly GTHX was in red as seen in intraday trades today. With action -22.20%, the performance over the past five days has been red. The drop to weekly highs of 4.76 subtracted -13.45% to the stock’s daily price. The company’s shares are showing year-to-date upside of 16.07%, with the 5-day performance at -22.20% in the red. However, in the 30-day time frame, G1 Therapeutics Inc (NASDAQ:GTHX) is -11.28% down.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

G1 Therapeutics Inc (GTHX) estimates and forecasts

Data shows that the G1 Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 108.24% over the past 6 months, a 41.94% in annual growth rate that is considerably higher than the industry average of 15.30%. Year-over-year growth is forecast to reach -12.40% down from the last financial year.

Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 16.45M. 6 analysts are of the opinion that G1 Therapeutics Inc’s revenue for the current quarter will be 18.01M. The company’s revenue for the corresponding quarters a year ago was 42.39M and 12.3M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -61.20%. The estimates for the next quarter sales put growth at 46.40%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 18.38%. The 2024 estimates are for G1 Therapeutics Inc earnings to increase by 39.65%.